Complications of Central Venous Catheters Used for the Treatment of Acute Hematogenous Osteomyelitis

Ruebner, Rebecca L.; Keren, Ron; Coffin, Susan; Chu, Jaclyn; Horn, David L.; Zaoutis, Theoklis E.

doi:10.1542/peds.2005-1465

Cited by 91 publications

(60 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Its good oral absorption makes it an important option in the therapy of the outpatients or as a follow up after an intravenous (IV) therapy (de-escalation). This permits an early transition to the outpatient management of the susceptible infections without the complications of a continued IV access [18]. It is effective against both the methicillin resistant and the methicillin sensitive Staphylococcal infections [1].…”

Section: Discussionmentioning

confidence: 99%

The Prevalence of Inducible Clindamycin Resistance Among Staphylococci in a Tertiary Care Hospital – A Study from the Garhwal Hills of Uttarakhand, India

Juyal¹

2013

JCDR

View full text Add to dashboard Cite

Objective: This study was undertaken to assess the frequency of the phenotypic expression of the inducible resistance to clindamycin which was due to the expression of the erm genes in various clinical isolates of the Staphylococcus species. Results: Among the 373 clinical isolates of Staphylococci which were studied, 134 isolates showed a discordant resistance pattern. Among these discordant strains, 45 (33.6%) isolates were D-test positive, which had inducible clindamycin resistance and belonged to the inducible macrolide lincosamide streptogramin-B phenotype (MLSBi). 89 (66.4%) isolates were D-test negative and they belonged to the macrolide streptogramin phenotype (MS). Among the MLSBi phenotypes, 6 (13.3%) isolates were methicillin-resistant Staphylococcus aureus (MRSA), 13 (28.9%) were Methicillin-sensitive S.aureus (MSSA) and 26 (57.8%) were coagulase negative staphylococci (CONS). Materials and Methods

show abstract

Section: Discussionmentioning

confidence: 99%

The Prevalence of Inducible Clindamycin Resistance Among Staphylococci in a Tertiary Care Hospital – A Study from the Garhwal Hills of Uttarakhand, India

Juyal¹

2013

JCDR

View full text Add to dashboard Cite

show abstract

“…An early switch to oral therapy is particularly important for children, as the risk for central line-related complications is high. Ruebner et al found that of 75 patients who received Ͼ2 weeks of treatment for acute OM through a central venous catheter (CVC), 41% developed at least one CVC-related complication (515).…”

Section: Osteoarticular Infections In Childrenmentioning

confidence: 99%

Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management

et al. 2015

View full text Add to dashboard Cite

SUMMARY Staphylococcus aureus is a major human pathogen that causes a wide range of clinical infections. It is a leading cause of bacteremia and infective endocarditis as well as osteoarticular, skin and soft tissue, pleuropulmonary, and device-related infections. This review comprehensively covers the epidemiology, pathophysiology, clinical manifestations, and management of each of these clinical entities. The past 2 decades have witnessed two clear shifts in the epidemiology of S. aureus infections: first, a growing number of health care-associated infections, particularly seen in infective endocarditis and prosthetic device infections, and second, an epidemic of community-associated skin and soft tissue infections driven by strains with certain virulence factors and resistance to β-lactam antibiotics. In reviewing the literature to support management strategies for these clinical manifestations, we also highlight the paucity of high-quality evidence for many key clinical questions.

show abstract

“…Central venous lines or PICCs and OPAT has attendant risks, with 3-11% of central venous line-associated infection noted in the USA. 57,58 Additional or second-line antibiotics for complex disease or where resistant pathogens are identified…”

Section: Continuation Of Intravenous Antibiotics For More Than 2 Weeksmentioning

confidence: 99%

Duration of intravenous antibiotic therapy for children with acute osteomyelitis or septic arthritis: a feasibility study

Sukhtankar

Arch

Ahmad

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

Declared competing interests of authors: Saul N Faust was UK chief investigator and University Hospital Southampton NHS Foundation Trust principal investigator for a Cubist-sponsored clinical trial of daptomycin against standard of care antibiotic therapy in paediatric osteomyelitis. All funds were paid into accounts within the NHS trust or university and not paid as personal fees. He reports consultancy fees for advisory board participation paid into accounts within the NHS trust or university (not personal fees) from vaccine manufacturers and antimicrobial agent manufacturers, including AstraZeneca, Cubist, Merck, GlaxoSmithKline (GSK) and Pfizer, outside the submitted work. He acts as principal investigator for clinical trials and other studies conducted on behalf of University Hospital Southampton NHS Foundation Trust/ University of Southampton that are sponsored by vaccine manufacturers and antimicrobial agents, and has participated in advisory boards for vaccine manufacturers. Adam Finn reports grants and personal fees from Sanofi Pasteur MSD Ltd (SPMSD), and grants and personal fees from GSK, outside the submitted work. In addition, prior to October 2014, the University of Bristol and University Hospitals Bristol NHS Foundation Trust received funding for research conducted by Adam Finn and for consultancy and lectures from Pfizer, GSK, SPMSD and Novartis, who manufacture licensed and developmental meningococcal vaccines. Stuart C Clarke acts as principal investigator for clinical trials and other studies conducted on behalf of University Hospital Southampton NHS Foundation Trust/University of Southampton that are sponsored by vaccine manufacturers but receive no personal payments from them. He has participated in advisory boards for vaccine manufacturers and has received financial assistance from vaccine manufacturers to attend conferences, but receives no personal payments for this work. All grants and honoraria are paid into accounts within the respective NHS trusts or universities. Jethro Herberg reports that he was an investigator for a Cubist-sponsored clinical trial of daptomycin against standard of care antibiotic therapy in paediatric osteomyelitis; he received no personal payments. Andrew Riordan reports that the trust, but not he, has received funding for research sponsored by vaccine manufacturers and antimicrobial agents. He was lead editor for an e-learning package on meningitis produced by the Royal College of Paediatric and Child Health, funded by an unrestricted grant from Novartis Vaccines. Marieke Emonts was Newcastle upon Tyne Hospitals Foundation Trust's principal investigator for a Cubist-sponsored clinical trial of daptomycin against standard of care antibiotic therapy in paediatric osteomyelitis. All grants and honoraria are paid into accounts within the NHS trust or university; she received no personal payment of any kind. Marieke Emonts reports acting as site principle investigator on behalf of the Newcastle upon Tyne Hospitals Foundation Trust/Newcastle University for clinical tr...

show abstract

Complications of Central Venous Catheters Used for the Treatment of Acute Hematogenous Osteomyelitis

Cited by 91 publications

References 24 publications

The Prevalence of Inducible Clindamycin Resistance Among Staphylococci in a Tertiary Care Hospital – A Study from the Garhwal Hills of Uttarakhand, India

The Prevalence of Inducible Clindamycin Resistance Among Staphylococci in a Tertiary Care Hospital – A Study from the Garhwal Hills of Uttarakhand, India

Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management

Duration of intravenous antibiotic therapy for children with acute osteomyelitis or septic arthritis: a feasibility study

Contact Info

Product

Resources

About